June 19, 2017 / 11:16 AM / a year ago

Seattle Genetics to halt late-stage study of leukemia drug

June 19 (Reuters) - U.S. drug developer Seattle Genetics Inc said on Monday it would discontinue a late-stage study of its drug to treat older patients with acute myeloid leukemia due to safety concerns.

The trial data showed a higher rate of deaths in patients who took the drug, vadastuximab talirine, compared to those on a placebo, the company said. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below